Aspirin for primary prevention of atherosclerotic disease in Japan

Journal of Atherosclerosis and Thrombosis

Volumn 14, Issue 4, 2007, Pages 159-166

  Morimoto, Takeshi ^a   Nakayama, Masafumi ^b   Saito, Yoshihiko ^c   Ogawa, Hisao ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Coronary heart disease; Diabetes; Epidemiology; Randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ASIAN; ATHEROSCLEROSIS; ETHNOLOGY; HUMAN; JAPAN; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; ATHEROSCLEROSIS; HUMANS; JAPAN;

EID: 38449108099     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E482     Document Type: Review

References (40)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, and Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 2006; 367:1747-1757
2. Levi F, Lucchini F, Negri E, and La Vecchia C: Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart, 2002; 88:119-124
3. Kitamura A, Iso H, Iida M, Naito Y, Sato S, Jacobs DR, Nakamura M, Shimamoto T, and Komachi Y: Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med, 2002; 112:104-109
4. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, and Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke, 2003; 34:2349-2354
5. Morimoto T, Fukui T, Lee TH, and Matsui K: Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med, 2004; 117:459-468
6. Dalen JE: Aspirin to prevent heart attack and stroke: what's the right dose? Am J Med, 2006; 119:198-202
7. Weisman SM and Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med, 2002; 162:2197-2202
8. Hennekens CH and Buring JE: Aspirin in the primary prevention of cardiovascular disease. Cardiol Clin, 1994; 12:443-450
9. Hayden M, Pignone M, Phillips C, and Mulrow C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 2002; 136:161-172
10. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, and Doll R: Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed), 1988, 296:313-316
11. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med, 1989; 321:129-135
12. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet, 1998; 351:233-241
13. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, and Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998; 351:1755-1762
14. de Gaetano G: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randornised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet, 2001; 357:89-95
15. Eidelman RS, Hebert PR, Weisman SM, and Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med, 2003; 163:2006-2010
16. Ayala C, Croft JB, Greenlund KJ, Keenan NL, Donehoo RS, Malarcher AM, and Mensah GA: Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995-1998. Stroke, 2002; 33:1197-1201
17. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med, 2002; 136:157-160
18. Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, Ishikawa K, Masuda Y, Yamaguchi T, Motomiya T, and Tamura Y: Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol, 1999; 83:1308-1313
19. Suerbaum S and Michetti P: Helicobacter pylori infection. N Engl J Med, 2002; 347:1175-1186
20. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, and Sung JJ: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med, 2001; 344:967-973
21. Ohkuma H, Fujita S, and Suzuki S: Incidence of aneurysmal subarachnoid hemorrhage in Shimokita, Japan, from 1989 to 1998. Stroke, 2002; 33:195-199
22. D'Agostino RB, Wolf PA, Belanger AJ, and Kannel WB: Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke, 1994; 25:40-43
23. Iso H, Date C, Yamamoto A, Toyoshima H, Tanabe N, Kikuchi S, Kondo T, Watanabe Y, Wada Y, Ishibashi T, Suzuki H, Koizumi A, Inaba Y, Tamakoshi A, and Ohno Y: Perceived mental stress and mortality from cardiovascular disease among Japanese men and women: the Japan Collaborative Cohort Study for Evaluation of Cancer Risk Sponsored by Monbusho (JACC Study). Circulation, 2002; 106:1229-1236
24. Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, Willett WC, and Manson JE: Prospective study of aspirin use and risk of stroke in women. Stroke, 1999; 30:1764-1771
25. Joint Research Committee for Cardiac Diseases Guidelines. Guidelines on primary prevention of coronary heart diseaseIn Japanese). Jpn Circ J, 2001; 65(Suppl V):999-1065
26. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, and Kromhout D: The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med, 2000; 342:1-8
27. Sarti C, Rastenyte D, Cepaitis Z, and Tuomilehto J: International trends in mortality from stroke, 1968 to 1994. Stroke, 2000; 31:1588-1601
28. Sekikawa A, Kuller LH, Ueshima H, Park JE, Suh I, Jee SH, Lee HK, and Pan WH: Coronary heart disease mortality trends in men in the post World War II birth cohorts aged 35-44 in Japan, South Korea and Taiwan compared with the United States. Int J Epidemiol, 1999; 28:1044-1049
29. Khor GL: Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr, 2001; 10:76-80
30. Sudlow C: Antiplatelet treatment. Clinical Evidence., 7 ed. London: BMJ Publishing Group, 2002; 110-112
31. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, and Kronmal RA: Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol, 2000; 57:326-332
32. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr., Jackson CM, and Pullicino P: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med, 2001; 345:1444-1451
33. Lauer MS: Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med, 2002; 346:1468-1474
34. Wolf PA, D'Agostino RB, Belanger AJ, and Kannel WB: Probability of stroke: a risk profile hom the Framingham Study. Stroke, 1991; 22:312-318.
35. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, and Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97:1837-1847
36. Rodriguez BL, D'Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, Ross GW, Silbershatz H, Higgins MW, Popper J, Wolf PA, and Curb JD: Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke, 2002; 33:230-236
37. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, and Yoshitake T. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes, 1996; 45 Suppl 3:S14-16
38. Beckman JA, Creager MA, and Libby P: Diabetes and atherosclerosis: epidemiolog, pathophysiology, and management. Jam, 2002; 287:2570-2581
39. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, and Nicolucci A: Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care, 2003; 26:3264-3272
40. Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) trial (http://clinicaltrials.gov/show/NCT00110448)